HRP980461B1 - Pharmaceutical suspension comprising nevirapine hemihydrate - Google Patents

Pharmaceutical suspension comprising nevirapine hemihydrate

Info

Publication number
HRP980461B1
HRP980461B1 HR980461A HRP980461A HRP980461B1 HR P980461 B1 HRP980461 B1 HR P980461B1 HR 980461 A HR980461 A HR 980461A HR P980461 A HRP980461 A HR P980461A HR P980461 B1 HRP980461 B1 HR P980461B1
Authority
HR
Croatia
Prior art keywords
pharmaceutical suspension
nevirapine hemihydrate
nevirapine
hemihydrate
pharmaceutical
Prior art date
Application number
HR980461A
Other languages
English (en)
Inventor
Karl Georg Grozinger
Amale Ayoub Hawi
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22006658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP980461(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of HRP980461A2 publication Critical patent/HRP980461A2/hr
Publication of HRP980461B1 publication Critical patent/HRP980461B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR980461A 1997-08-25 1998-08-24 Pharmaceutical suspension comprising nevirapine hemihydrate HRP980461B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5680397P 1997-08-25 1997-08-25

Publications (2)

Publication Number Publication Date
HRP980461A2 HRP980461A2 (en) 1999-06-30
HRP980461B1 true HRP980461B1 (en) 2002-08-31

Family

ID=22006658

Family Applications (1)

Application Number Title Priority Date Filing Date
HR980461A HRP980461B1 (en) 1997-08-25 1998-08-24 Pharmaceutical suspension comprising nevirapine hemihydrate

Country Status (38)

Country Link
US (2) US6172059B1 (el)
EP (1) EP1019058B1 (el)
JP (1) JP3472261B2 (el)
KR (1) KR100426516B1 (el)
CN (1) CN1197578C (el)
AR (2) AR016869A1 (el)
AT (1) ATE326971T1 (el)
AU (1) AU742761B2 (el)
BG (1) BG64337B1 (el)
BR (1) BR9811994B1 (el)
CA (1) CA2301646C (el)
CL (1) CL2008003111A1 (el)
CO (1) CO4970742A1 (el)
CY (1) CY1105228T1 (el)
CZ (1) CZ290667B6 (el)
DE (1) DE69834655T2 (el)
DK (1) DK1019058T3 (el)
EG (1) EG24075A (el)
ES (1) ES2265666T3 (el)
HK (1) HK1027975A1 (el)
HR (1) HRP980461B1 (el)
HU (1) HU226063B1 (el)
ID (1) ID21650A (el)
IL (1) IL134185A (el)
MY (1) MY122272A (el)
NO (1) NO326226B1 (el)
NZ (1) NZ503414A (el)
PE (1) PE105799A1 (el)
PL (1) PL192361B1 (el)
PT (1) PT1019058E (el)
RS (1) RS49808B (el)
RU (1) RU2196584C2 (el)
SA (1) SA98190680B1 (el)
TR (1) TR200000490T2 (el)
TW (1) TW450812B (el)
UA (1) UA44370C2 (el)
WO (1) WO1999009990A1 (el)
ZA (1) ZA987623B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092095A1 (en) * 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
EP1504040A1 (en) * 2002-04-23 2005-02-09 Boehringer Ingelheim Pharmaceuticals Inc. Method for reduction of residual organic solvent in carbomer
AU2006286314A1 (en) * 2005-08-31 2007-03-08 Cipla Limited Pharmaceutical combinations containing lamivudine, stavudine and nevirapine
EP2306980A2 (en) * 2008-06-30 2011-04-13 Tibotec Pharmaceuticals Powders for reconstitution
US9273049B2 (en) * 2009-11-10 2016-03-01 North-West University Method for increasing the solubility of nevirapine
BR112012014762A2 (pt) * 2009-12-17 2016-03-29 Univ Northwest forma polimorfa de nevirapina e sua preparação

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) * 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
CA2030056C (en) * 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5571912A (en) * 1990-10-19 1996-11-05 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the preparation of 5,11-dihydro-6h-dipyrido [3,2-b:2',3'-e][1,4]diazepines
DE4403311C1 (de) * 1994-02-03 1995-04-20 Boehringer Ingelheim Kg Verfahren zur Herstellung von Nevirapine (11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4-diazepin]-6-on)

Also Published As

Publication number Publication date
CA2301646C (en) 2008-11-18
PE105799A1 (es) 1999-11-16
BR9811994A (pt) 2000-09-05
IL134185A (en) 2005-11-20
TW450812B (en) 2001-08-21
RS49808B (sr) 2008-08-07
BG64337B1 (bg) 2004-10-29
BR9811994B1 (pt) 2013-11-19
WO1999009990A1 (en) 1999-03-04
AR016869A1 (es) 2001-08-01
AU742761B2 (en) 2002-01-10
PL338828A1 (en) 2000-11-20
AU8777198A (en) 1999-03-16
ID21650A (id) 1999-07-08
DK1019058T3 (da) 2006-06-12
EP1019058A1 (en) 2000-07-19
HUP0003093A2 (hu) 2001-08-28
EG24075A (en) 2008-05-11
CA2301646A1 (en) 1999-03-04
EP1019058A4 (en) 2004-11-10
CY1105228T1 (el) 2010-03-03
YU9800A (sh) 2001-12-26
KR100426516B1 (ko) 2004-04-13
IL134185A0 (en) 2001-04-30
UA44370C2 (uk) 2002-02-15
ES2265666T3 (es) 2007-02-16
BG104133A (en) 2000-08-31
DE69834655D1 (de) 2006-06-29
ZA987623B (en) 2000-03-22
CL2008003111A1 (es) 2009-09-11
EP1019058B1 (en) 2006-05-24
DE69834655T2 (de) 2006-12-14
SA98190680B1 (ar) 2006-04-04
CN1197578C (zh) 2005-04-20
TR200000490T2 (tr) 2000-08-21
PL192361B1 (pl) 2006-10-31
JP3472261B2 (ja) 2003-12-02
HU226063B1 (hu) 2008-04-28
CZ2000694A3 (cs) 2000-09-13
ATE326971T1 (de) 2006-06-15
PT1019058E (pt) 2006-08-31
HK1027975A1 (en) 2001-02-02
NO20000906L (no) 2000-02-24
US6172059B1 (en) 2001-01-09
JP2001513564A (ja) 2001-09-04
HRP980461A2 (en) 1999-06-30
AR083451A2 (es) 2013-02-27
RU2196584C2 (ru) 2003-01-20
NO326226B1 (no) 2008-10-20
KR20010023257A (ko) 2001-03-26
NZ503414A (en) 2002-11-26
US6255481B1 (en) 2001-07-03
CO4970742A1 (es) 2000-11-07
NO20000906D0 (no) 2000-02-24
MY122272A (en) 2006-04-29
CN1268055A (zh) 2000-09-27
CZ290667B6 (cs) 2002-09-11

Similar Documents

Publication Publication Date Title
PL340337A1 (en) Drugs
GB9706089D0 (en) Pharmaceutical composition
GB9700504D0 (en) Pharmaceutical compounds
SG76535A1 (en) Pharmaceutical agents
GB9726563D0 (en) Novel pharmaceutical
GB9726566D0 (en) Novel pharmaceutical
GB9815532D0 (en) Pharmaceutical suspension formulation
EG23694A (en) Novel pharmaceutical
EP1003495A4 (en) PHARMACEUTICAL COMPOUNDS
GB9716244D0 (en) Pharmaceutical compounds
GB9717444D0 (en) Pharmaceutical composition
ZA982073B (en) Pharmaceutical preparation
HUP0002455A3 (en) Gastric-retained pharmaceutical composition
GB9717428D0 (en) Pharmaceutical composition
EG24075A (en) Pharmaceutical suspension comprising nevirapine hemihydrate
ZA98300B (en) Pharmaceutical compounds
GB9717770D0 (en) Pharmaceutical composition
GB9706376D0 (en) Novel pharmaceutical
GB2321190B (en) Pharmaceutical composition
GB9726781D0 (en) Pharmaceutical composition
IL120319A0 (en) Pharmaceutical preparation
CA82556S (en) Capsule
GB9723472D0 (en) Suspension means
GB9710525D0 (en) Pharmaceutical composition
GB9727238D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20140729

Year of fee payment: 17

PBON Lapse due to non-payment of renewal fee

Effective date: 20150824